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Background: Rivaroxaban reduces stroke in patients with atrial fibrillation (AF). Left atrium (LA) plays a critical role
in the pathophysiology of AF. However, the electromechanical effects of rivaroxaban on LA are not clear.
Results: Conventional microelectrodes and a whole-cell patch-clamp were used to record the action potentials (APs)
and ionic currents in rabbit LA preparations and isolated single LA cardiomyocytes before and after the administration of
rivaroxaban. Rivaroxaban (10, 30, 100, and 300 nM) concentration-dependently reduced LA (n = 7) AP durations at 90%
repolarization (APD90) from 76 ± 2 to 79 ± 3, 67 ± 4 (P < 0.05, vs. control), 59 ± 5, (P < 0.01, vs. control), and 56 ± 4 ms
(P < 0.005, vs. control), respectively. Rivaroxaban (10, 30, 100, and 300 nM) concentration-dependently
increased the LA (n = 7) diastolic tension by 351 ± 69 (P < 0.05, vs. control), 563 ± 136 (P < 0.05, vs. control),
582 ± 119 (P < 0.05, vs. control), and 603 ± 108 mg (P < 0.005, vs. control), respectively, but did not change LA
contractility. In the presence of L-NAME (100 μM) and indomethacin (10 μM), additional rivaroxaban (300
nM) treatment did not significantly further increase the LA (n = 7) diastolic tension, but shortened the APD90
from 73 ± 2 to 60 ± 6 ms (P < 0.05, vs. control). Rivaroxaban (100 nM) increased the L-type calcium current
and ultra-rapid delayed rectifier potassium current, but did not change the transient outward potassium
current in isolated LA cardiomyocytes.
Conclusions: Rivaroxaban modulates LA electrical and mechanical characteristics with direct ionic current effects.
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Arial fibrillation (AF) is the most common sustained
arrhythmia which predisposes to early activation of
platelets, induction of coagulation factors, and ultimately
formation of thrombi in left atrium (LA), which contrib-
utes to thromboembolic morbidity and mortality [1,2].
LA plays a major role in the genesis of AF, and also har-
bors activated platelets and increased prothrombotic fac-
tors [2]. These AF-activated prothrombotic factors,
activated factor X (FXa) and downstream thrombin, may
exert their electromechanical effects on cardiomyocytes
other than thrombosis through activating protease-
activated receptors (PARs) [3]. FXa elicits intracellular
signaling responses through the activated PAR2 and* Correspondence: yjchen@tmu.edu.tw
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reproduction in any medium, provided the orpossibly also through PAR1 in endothelial and smooth
muscle cells [4]. Activated PAR1 coupled with Gq, Gi,
and/or G12/13 stimulation mediated nitric oxide (NO)
production by NO synthase (NOS) [5]. In various tissues,
PAR2 activation caused arachidonic acid release and
prostanoid formation which involved cyclooxygenase
(COX) induction via multiple signaling pathways [5].
Accordingly, AF-induced FXa which activates PAR1 and
PAR2 could modulate LA electrical and mechanical char-
acteristics through NO and prostanoid formation [5,6].
Rivaroxaban selectively binds to the FXa and reduces
thrombin formation, which prevents stroke in AF patients
[7]. However, it is not clear whether rivaroxaban modu-
lates electrical and mechanical characteristics of the LA.
The purposes of this study were to investigate the
electrical and mechanical effects of rivaroxaban on
LA and evaluate the roles of NOS and COX in the effects
of FXa.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Electromechanical and pharmacological studies of the LA
preparations
Experiments in this study conformed to the institutional
Guide for the Care and Use of Laboratory Animals.
Male rabbits (weighing 1 ~ 2 kg) were anesthetized
with an intraperitoneal injection of sodium pentobar-
bital (100 mg/kg). A midline thoracotomy was then
performed, and the heart and lungs were removed as
described previously [8,9]. To dissect the LA, the LA
was opened by an incision along the mitral valve annu-
lus, extending from the coronary sinus to the septum,
in Tyrode’s solution with a composition (in mM) of 137
NaCl, 4 KCl, 15 NaHCO3, 0.5 NaH2PO4, 0.5 MgCl2, 2.7
CaCl2, and 11 dextrose. Preparations were connected to
a WPI model FD223 electrometer under a tension of
150 mg as described previously [10,11]. One end of
the preparations was pinned with needles to the bot-
tom of a tissue bath. The other end was connected to
a Grass FT03C force transducer with a silk thread.
The adventitial or epicardial side of the preparations
faced upwards. The LA tissue strips were superfused
at a constant rate (3 ml/min) with Tyrode’s solutionFigure 1 Effects of rivaroxaban on the left atrial (LA) action potential
that rivaroxaban (10, 30, 100, and 300 nM) concentration-dependently shor
membrane potential (RMP), AP amplitude (APA), and contractile forces of L
** P < 0.01, *** P < 0.005 vs. control.saturated with a 97% O2-3% CO2 gas mixture. The
temperature was maintained at 37°C, and the prepara-
tions were allowed to equilibrate for 1 h before the
electrophysiological assessment.
Transmembrane action potentials (APs) were recorded
by machine-pulled glass capillary microelectrodes filled
with 3 mol/L of KCl which were connected to a WPI
Duo 773 electrometer under a tension of 150 mg. Elec-
trical and mechanical events (contractile force and dia-
stolic tension) were simultaneously displayed on a Gould
4072 oscilloscope and a Gould TA11 recorder. Using a
data acquisition system, signals were recorded with DC
coupling and a 10-kHz low-pass filter cutoff frequency.
Signals were recorded digitally with a 16-bit accuracy at
a rate of 125 kHz. Electrical stimulation was provided
using a Grass S88 stimulator through a Grass SIU5B
stimulus isolation unit. The AP amplitude (APA) was
obtained by measuring the difference between the rest-
ing membrane potential (RMP) or maximum diastolic
potential and the peak of AP depolarization. AP dura-
tions (APDs) at repolarization of 90%, 50%, and 20% of
the APA were respectively measured as APD90, APD50,
and APD20. The RMP, APA, APD90, APD50, APD20, and(AP) and contractility. An example and average data (n = 7) show
tened AP durations (APD20, APD50, and APD90) of LA. The resting
A did not significantly change with rivaroxaban treatment. * P < 0.05,
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the LA before and after the sequential administration of
rivaroxaban (10, 30, 100, and 300 nM). In order to study
the mechanical effects of rivaroxaban, an NG-nitro-L-
arginine methyl ester (L-NAME) solution (an NOS in-
hibitor, 100 μM) and indomethacin (a non-selective
COX inhibitor, 10 μM) solution and rivaroxaban solution
(300 nM) were sequentially added to LA preparations.
Isolation of LA cardiomyocytes and a whole-cell
patch-clamp
Single LA myocytes were enzymatically dissociated
through the same procedure as described previously
[12]. A whole-cell perforated with amphotericin B of
300 μg/ml (for L-type calcium current, ICa-L) or ruptured
(for others) patch clamp was performed in single isolated
cardiomyocyte before and after the administration of
rivaroxaban (100 nM) using an Axopatch 1D amplifier
(Axon Instruments, Foster City, CA, USA) at 35 ± 1°C
[12]. Borosilicate glass electrodes (o.d., 1.8 mm) with tip
resistances of 3 ~ 5 MΩ were used. Before the formation
of the membrane-pipette seal, the tip potentials were
zeroed in Tyrode’s solution. The junction potentials be-
tween the bath and pipette solution (9 mV) were
corrected for the AP recordings. APs were recorded inFigure 2 Effect of rivaroxaban with and without NG-nitro-L-arginine m
diastolic tension. (A) An example and average data (n = 7) show that riva
LA. (Δ, change in the diastolic tension) (B) An example and average data (n
sequentially increased the diastolic tension of the LA. * P < 0.05, ** P < 0.01the current-clamp mode, and the ionic currents were
recorded in the voltage-clamp mode. A small hyperpo-
larizing step from a holding potential of −50 mV to a
test potential of −55 mV for 80 ms was delivered at the
beginning of each experiment. The area under the cap-
acitative currents was divided by the applied voltage step
to obtain the total cell capacitance. Normally 60% ~ 80%
series resistance (Rs) was electronically compensated for.
APs were elicited in cells from the LA through brief
current pulses at 1 Hz. The extracellular solution
contained the basic composition (in mM) of NaCl 137,
KCl 5.4, HEPES 10, MgCl2 0.5, CaCl2 1.8, and glucose
10. The solution was titrated to a pH of 7.4 with
NaOH. Micropipettes were filled with a solution
containing (in mM) CsCl 130, MgCl2 1, Mg2ATP 5,
HEPES 10, EGTA 10, NaGTP 0.1, and Na2 phospho-
creatine 5, (adjusted to a pH of 7.2 with CsOH) for the
ICa-L and containing (in mM) KCl 20, K aspartate 110,
MgCl2 1, Mg2ATP 5, HEPES 10, EGTA 0.5, LiGTP 0.1,
and Na2 phosphocreatine 5, (adjusted to a pH of 7.2
with KOH) for the AP and potassium currents. The ICa-L
was measured as an inward current during depolarization
from a holding potential of −50 mV to testing potentials
ranging from −40 to +60 mV in 10-mV steps for 300 ms
at a frequency of 0.1 Hz. The NaCl and KCl in theethyl ester (L-NAME) or indomethacin on the left atrial (LA)
roxaban concentration-dependently increased the diastolic tension of
= 7) show that L-NAME, indomethacin, and additional rivaroxaban
, *** P < 0.005 vs. control.
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and CsCl. The transient outward potassium current
(Ito) was studied with a double-pulse protocol. A 30-ms
pre-pulse from −80 to −40 mV was used to inactivate
the sodium channels, followed by a 300-ms test pulse
to +60 mV in 10-mV steps at a frequency of 0.1 Hz.
CdCl2 (200 μM) was added to the bath solution to in-
hibit the ICa-L. The Ito was measured as the difference
between the peak outward current and steady-state
current [13]. The ultra-rapid delayed rectifier potassium
current (IKur) was studied with a double-pulse protocol,
consisting of a 100-ms depolarizing pre-pulse to +40 mV
from a holding potential of −50 mV, followed by 150-ms
voltage steps from −40 to +60 mV in 10-mV increments
at room temperature to provide an adequate temporal
resolution. The IKur was measured as 4-aminopyridine
(1 mM)-sensitive currents [14,15].
Statistical analysis
All continuous variables are expressed as the mean ±
standard error of the mean (SEM). A one-way repeated-Figure 3 Effects of rivaroxaban (300 nM) with and without NG-nitro-L-
and on the left atrial (LA) action potential (AP) and contractility. An ex
300 nM) solutions concentration-dependently shortened the 90% repolariza
(RMP), AP amplitude (APA), and contractile forces of LA did not significantly
treatment. * P < 0.05 vs. control.measures analysis of variance (ANOVA) was used to
compare the difference before and after drug administra-
tion on LA. The electrophysiological and mechanical
characteristics between different groups were compared
by a Wilcoxon rank-sum test or unpaired t-test depend-
ing on the outcome of the normality test. A P value of
less than 0.05 was considered statistically significant.
Results
Rivaroxaban affects the electric and mechanical
characteristics of LA
As shown in Figure 1, rivaroxaban (10, 30, 100, and
300 nM) concentration-dependently reduced the APD20,
APD50, and APD90 in LA. However, rivaroxaban did not
significantly affect the RMP, APA, or contractile force of
LA. Moreover, rivaroxaban (10, 30, 100, and 300 nM)
concentration-dependently increased LA diastolic
tension, which could not be reversed after washout
for 30 min (Figure 2A). The treatment with L-NAME
(100 μM), add-on indomethacin (10 μM), and add-
itional rivaroxaban (300 nM) increased the LA diastolicarginine methyl ester (L-NAME, 100 μM), or indomethacin (10 μM)
ample and average data (n = 7) show that rivaroxaban (10, 30, 100, and
tion of the AP duration (APD90) of LA. The resting membrane potential
change with L-NAME, indomethacin and additional rivaroxaban
Figure 5 Effect of rivaroxaban on L-type calcium current (ICa-L)
of left atrial (LA) myocytes. An example and average data show
the I-V relationship of the ICa-L before and after rivaroxaban (100 nM)
administration in LA myocytes (n = 11). * P < 0.05 vs. control. The
inset shows the clamp protocol.
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but did not affect contractile forces of LA (Figure 3). In
addition, the increment in diastolic tension by L-NAME
was less than that in the LA treated with 30 nM
rivaroxaban (P < 0.05), 100 nM rivaroxaban (P < 0.05),
and 300 nM rivaroxaban (P < 0.05). In the presence of
L-NAME, indomethacin administration (10 μM) fur-
ther increased the LA diastolic tension which was
comparable to that of LA treated with rivaroxaban (30,
100, and 300 nM). In the presence of L-NAME and
indomethacin, the additional rivaroxaban (300 nM)
treatment did not further significantly increase the LA
diastolic tension, and the overall increment in the LA
diastolic tension after treatment of rivaroxaban (300 nM)
did not differ in the presence or absence of L-NAME
and indomethacin.
As shown in Figure 3, in the presence of L-NAME
(100 μM) and indomethacin (10 μM), additional treat-
ment with rivaroxaban (300 nM) significantly shortened
the APD90 but did not affect the RMP or APA of LA.
Effects of rivaroxaban on AP configurations in LA
myocytes
Rivaroxaban had rapid effects on the electrical activity of
LA myocytes and reached a steady state in 3 ~ 5 min
after its superfusion. Figure 4 presents examples of theFigure 4 Effects of rivaroxaban on isolated left atrial (LA) myocytes. An example and average data show that rivaroxaban shortened the
action potential durations (APD20 and APD50) of LA (n = 7). * P < 0.05 vs. control.
Figure 6 Effects of rivaroxaban on the transient outward current (Ito) of left atrial (LA) myocytes. An example and average data show the
I-V relationship of the Ito before and after rivaroxaban administration in LA myocytes (n = 12). The inset shows the clamp protocol.
Figure 7 Effects of rivaroxaban on the ultra-rapid delayed
rectifier potassium current (IKur) of left atrial (LA)
cardiomyocytes. This figure shows a tracing and the I-V relationship
of the IKur before and after rivaroxaban (100 nM) administration in
LA myocytes (n = 12), *P < 0.05 vs. control. The inset shows the
clamp protocol.
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rivaroxaban (100 nM) administration (n = 7). Super-
fusion with rivaroxaban significantly reduced APD50 and
APD20 in LA myocytes. However, rivaroxaban (100 nM)
did not affect the APA or RMP in LA myocytes.
Effect of rivaroxaban on membrane currents of LA
myocytes
Figure 5 shows tracings and the I-V relationship of the
ICa-L before and after rivaroxaban (100 nM) administra-
tion in LA myocytes, and it was found that rivaroxaban
increased the peak ICa-L by 11.8% (elicited from −40 mV
to +60 mV, n = 11). However, as shown in Figure 6,
rivaroxaban (100 nM) did not significantly change the
Ito. Moreover, Figure 7 shows that rivaroxaban (100 nM)
significantly increased the peak IKur by 29.6% (elicited
from −40 mV to +60 mV, n = 12).
Discussion
To reduce thromboembolic complications with AF,
several new antithrombotic agents were developed
with non-inferior antithrombotic effects and fewer
hemorrhagic complications than the traditional vita-
min K antagonist [16,17]. It’s well known that AF-
activated prothrombotic factors, activated factor X
(FXa) and downstream thrombin, exert their electro-
mechanical effects on cardiomyocytes other than
thrombosis through activating protease-activated re-
ceptors (PARs) [3]. Accordingly, the reduction in FXa
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teristics of the LA by inhibiting NO and prostanoid
[4,5]. This study attempted to investigate the electrical
and mechanical effects of rivaroxaban on LA at com-
parable physiological doses and also evaluated the in-
hibitors of NOS and COX. Rivaroxaban reversibly
bound to the FXa and diminished PAR1 and PAR2 ac-
tivation. These two activated G-protein-coupled re-
ceptors promote the production of prostanoid and
NO which induce vascular dilatation and reduce wall
tension. In this study, rivaroxaban administration
resulted in concentration-dependent shortening of
APDs (Figure 1) and an increasing wall tension of LA
(Figure 3). Moreover, in Figures 1 and 3, the diastolic
tension increased earlier (with 10 nM rivaroxaban)
than the occurrence of APD shortening (with 30 nM
rivaroxaban). The earlier increased wall tension may also
have contributed to the shortening of the AP through
mechanoelectrical feedback [18-20], in addition to the
direct effects of rivaroxaban on LA cardiomyocytes.
According to a previous study, stretching of myo-
cardiocytes shortened the APD, which implies a possible
mechanism of electric modulation by rivaroxaban [21]. A
maximal plasma concentration (Cmax), of around 125 μg/L
or 300 nM, of rivaroxaban was reached within 2 ~ 4 h after
oral administration after a single oral dose in healthy
volunteers [22,23]. Therefore, the concentrations used
in this experiment are clinically relevant. However, there
is no report available so far to show that rivaroxaban ad-
ministered at clinically relevant dose increases atrial
diastolic pressure. Moreover, this study did not evaluate
the effects of rivaroxaban (300 nM) alone or L-NAME
with rivaroxaban on LA.
In this study, we found that L-NAME significantly in-
creased the LA wall tension but this effect is less than
that by rivaroxaban. This finding implied that blockage
of NOS mediated a portion of the effects of rivaroxaban
on LA to increase the wall tension. Additional adminis-
tration of indomethacin, which blocked COX and re-
duced prostanoid production, further elevated the wall
tension of LA to a level comparable to that induced by
rivaroxaban. In the presence of L-NAME and indo-
methacin, the additional administration of rivaroxaban
(300 nM) did not significantly increase the wall tension,
but the total increment in the wall tension was compar-
able to the increase by rivaroxaban (300 nM) as shown
in Figure 2. The blockage of the FXa by rivaroxaban re-
duced the production of NO and prostanoid, which co-
ordinately increased the wall tension of LA. The
blockage of NOS by L-NAME represented a partial
mechanical effect, while the additional blockage of
COX by indomethacin seemed to nearly complete the
mechanical effect of rivaroxaban on LA. However, the
sequential addition of L-NAME and indomethacin didnot significantly change the APDs, but additional
rivaroxaban (300 nM) treatment shortened the APD90
compared to the baseline (Figure 2). It is not clear
whether this electrical effect of rivaroxaban on LA is dir-
ectly mediated by rivaroxaban or resulted from dimin-
ished activation of PARs. Besides, we also didn’t use the
NOS and COX activator to elucidate the mechanisms of
rivaroxaban-increased diastolic tension in LA or their
direct AP and ionic effects in isolated LA myocytes.
In experiments on isolated single myocytes, we found
that rivaroxaban (100 nM) shortened the APD20 and
APD50, but did not affect the APD90, RMP, or APA.
The less shortening of the APD in isolated single
cardiomyocyte by rivaroxaban suggested that the greater
shortening of APD in LA tissue preparations may have
been caused by mechanoelectrical feedback due to the
increased wall tension with stretched myocytes in tissue
preparation experiments. The ionic current experiments
showed that rivaroxaban did not change the Ito but sig-
nificantly increased the IKur, which may have contrib-
uted to its effect in shortening the APD. Rivaroxaban
also increased the ICa-L, which may have been a result
of repolarization homeostasis and implies that the in-
creasing LA wall tension was due to intracellular cal-
cium loading. These findings suggest that rivaroxaban
at clinically relevant concentrations directly affects ionic
currents in LA myocytes. In order to correlate the clin-
ical settings, we use 100 nM of rivaroxaban to measure
its ionic current effects, which are closely related to the
known plasma concentrations in humans [24]. However,
it is not clear whether the higher concentration of
rivaroxaban (300 nM) may have stronger ionic effects.
Moreover, we did not use purified FX in the tissue
preparation experiments to elucidate its potential com-
petition effects to rivaroxaban.
Conclusions
Rivaroxaban modulates LA electrical characteristics with
direct effects on ionic currents, and regulates mechan-
ical characteristics, which can be attenuated by the inhi-
bitions on NOS and COX.
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